<DOC>
	<DOC>NCT01262118</DOC>
	<brief_summary>The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older Pregnant or lactating women Clinically significant systemic disease (other than RA for RA arm) Use of lipidregulating agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Cholesterol metabolism</keyword>
	<keyword>Cholesterol flux</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Tasocitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
</DOC>